GlassScriptPhysician profile
David J Thomason
NPI 1770878373
$7,326.98
in general payments reported to CMS, 2019-2025
58 companies · $870 in 2025
The $870 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $605 · 2021: $1,130 · 2022: $1,159 · 2023: $1,067 · 2024: $784 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,300.92 | 2019-2025 | Botox, Ubrelvy, Duopa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $844.83 | 2019-2025 | Relistor |
| Allergan, INC. | $540.37 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $406.36 | 2019-2022 | |
| Ucb, INC. | $290.66 | 2019-2025 | Briviact, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $263.61 | 2019-2025 | Austedo Xr, Austedo Xr |
| Scilex Pharmaceuticals INC. | $256.49 | 2019-2023 | Ztlido |
| Adamas Pharmaceuticals, INC. | $232.04 | 2019-2021 | |
| Lilly USA, LLC | $208.41 | 2019-2023 | Amyvid |
| Sk Life Science, INC. | $200.78 | 2021-2023 | |
| Tanabe Pharma America, INC. | $178.83 | 2019-2024 | |
| Merz Pharmaceuticals, LLC | $163.87 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Amgen INC. | $156.10 | 2019-2022 | |
| Lundbeck LLC | $146.38 | 2019-2022 | |
| Pacira Therapeutics, INC. | $144.50 | 2019-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Thomason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.